Regulatory Bayer gets swift review for Kerendia in type 1 diabetes PharmaphorumFDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum FDA starts a priority review of Bayer’s Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies. Metabolic & GLP-1 Read full story Post navigation Previous: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPDNext: FUJIFILM opens new iPSC facility in Madison, US Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
